Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.30M
Market Cap
$281.44M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Aug 05, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding198,199,460
10 Day Avg. Volume7,271,075
30 Day Avg. Volume4,296,691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside533.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Global ExpansionEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada, reflecting commitment to expand BDA's global access.
Legal SettlementEsperion has secured a legal settlement preventing companies from marketing a generic version of NEXLETOL in the U.S. prior to April 19, 2040, ensuring market exclusivity.
Sales GrowthEarly trends in 2Q25 BDA sales are encouraging, with prescription volume tracking approximately 8% higher than 1Q25.
Bears Say
CompetitionEsperion is making strides to position BDA as the drug of choice over statins and PCSK9 inhibitors, which indicates ongoing competition in the drug market.
Legal RisksSettlements with ANDA filers help avoid costly and lengthy legal processes typically associated with patent disputes, highlighting potential legal risks.
Esperion News
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.69 and its highest was $3.94 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $281.44M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 05, 2025 which is in 3 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.055.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.15.
How many shares outstanding does Esperion have?
Esperion has 198,199,460 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in ESPR
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (533.80% Upside)
$9.00 (533.80% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 544.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $50.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.52%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Company Deck
ESPR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.Read More>ESPR Stock 12 Month Forecast
Average Price Target
$9.00
▲(533.80%Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
1.74% Insiders
13.85% Mutual Funds
0.05% Other Institutional Investors
74.53% Public Companies and
Individual Investors